Skip to main content
Clinical Trials/KCT0004454
KCT0004454
Terminated
未知

Multicenter, therapeutic use observational study to evaluate the effects of concurrent therapy of Sarpogrelate on symptom improvement in patients with peripheral arterial disease

Kosin University Gospel Hospital0 sites115 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Kosin University Gospel Hospital
Enrollment
115
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients between the ages of 19 and 80
  • 2\. First administered or administered for less than three months of Sarpogrelate Hydrochloride to improve ischemic symptoms such as ulcers, pain and coldness caused by chronic arterial obstruction (Berger's disease, obstructive atherosclerosis, diabetic peripheral angiopathy, etc.)
  • 3\. Written informed consent by patient or his/her legal representative and agreed to participate in the study approved by the Institutional Review Board or ethics Committee

Exclusion Criteria

  • 1\. Overall life expectancy \< 2 year.
  • 2\. Any medically documented history of bleeding within a week of participating in the study
  • 3\. Persons with diseases that may increase bleeding during the study (Hemophilia, Capillary Placebo, Gastrointestinal Ulcers, Urinary Tract Bleeding, Hemoglobin, Vitreous Hemorrhage, etc.)
  • 4\. A female patient who is or may be pregnant
  • 5\. Female patients who are or will be breastfeeding during the study period
  • 6\. Patients who are not suitable for exercise therapy on their own due to cerebrovascular lesions, spinal diseases, muscle diseases, etc.
  • 7\. Patients with severe renal or hepatic disease

Outcomes

Primary Outcomes

Not specified

Similar Trials